Leonard T. Heffner

Association of busulfan area under the curve with veno-occlusive disease following BMT.

S P Dix, John R. Wingard, Richard E. Mullins et al. · PubMed · 1996 · 323 citations

Medicine, Hematology, Hematopathology +3

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

Paul G. Richardson, Wanling Xie, Constantine S. Mitsiades et al. · Journal of Clinical Oncology · 2009 · 272 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi et al. · The Lancet Oncology · 2016 · 236 citations

Life Sciences, Immunology, Pharmacotherapy +12

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

A K Nooka, Jonathan L. Kaufman, Samatha Muppidi et al. · Leukemia · 2013 · 195 citations

Medicine, Oncology, Pharmacotherapy +14

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Steven Coutré, Michael Y. Choi, Richard R. Furman et al. · Blood · 2018 · 132 citations · Full text

Medicine, Hematology, Oncology +14